We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Abmaxis Achieves Milestone in Collaboration With Merck
News

Abmaxis Achieves Milestone in Collaboration With Merck

Abmaxis Achieves Milestone in Collaboration With Merck
News

Abmaxis Achieves Milestone in Collaboration With Merck

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Abmaxis Achieves Milestone in Collaboration With Merck "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Abmaxis, Inc. has announced that it has achieved a major milestone under its collaboration agreement with Merck & Co., Inc.

Under the terms of the agreement, Abmaxis was to optimize an undisclosed Merck human monoclonal antibody for potential therapeutic use.

The Abmaxis team has re-engineered Merck's human monoclonal antibody and improved antibody affinity 70-fold while retaining its specificity, triggering a milestone payment from Merck.

“It has been a rewarding experience for the Abmaxis team to work with Merck on this technically challenging project and this achievement demonstrates the advantages of our Abmaxis in-silico Immunization (AISIM™) technology platform over conventional antibody engineering technologies,” said Peter Luo, Ph.D., Chief Technology Officer of Abmaxis.

“The results we were able to achieve for Merck are an important validation of our structure-centric approach towards antibody engineering,” added Shirley Clayton, President and Chief Executive Officer.

“It would be a challenge to the conventional sequence-centric antibody engineering approach to achieve such a significant improvement.”

Advertisement